Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Analyst sentiment is mixed: Seven brokerages give Kestra Medical Technologies a consensus “Hold” rating, with one sell, two hold, and four buy recommendations. The average 12-month price target is $28.14 versus the stock’s reported $25.54 price.
• Insiders have recently sold shares: Insiders sold 238,164 shares worth approximately $5.7 million over the past 90 days, though the disclosed transactions were intended to cover tax withholding on vested equity awards.
• Financial performance remains pressured: Kestra reported a quarterly loss of $0.67 per share, missing estimates by $0.08, on revenue of $28.64 million. Analysts expect a full-year loss of $2.29 per share.

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have received a consensus rating of "Hold" from the seven brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $28.1429.

A number of research analysts recently weighed in on the company. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. BTIG Research restated a "buy" rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. Oppenheimer began coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a "market perform" rating on the stock. Wall Street Zen raised shares of Kestra Medical Technologies from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They set an "overweight" rating and a $30.00 price target for the company.

Insiders Place Their Bets

In other news, insider Brian Webster sold 51,900 shares of the company's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00. Following the completion of the sale, the insider owned 475,215 shares in the company, valued at $11,652,271.80. This represents a 9.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Traci S. Umberger sold 8,752 shares of the stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $22.60, for a total transaction of $197,795.20. Following the completion of the sale, the insider owned 206,995 shares of the company's stock, valued at approximately $4,678,087. This represents a 4.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 238,164 shares of company stock worth $5,700,952 in the last 90 days. Company insiders own 5.30% of the company's stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its position in Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after purchasing an additional 474 shares during the last quarter. Brown Brothers Harriman & Co. increased its position in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company's stock valued at $74,000 after purchasing an additional 656 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Kestra Medical Technologies by 7.3% during the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company's stock worth $307,000 after purchasing an additional 874 shares during the period. Farther Finance Advisors LLC bought a new stake in shares of Kestra Medical Technologies during the 4th quarter worth $31,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of Kestra Medical Technologies by 34.6% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company's stock worth $144,000 after buying an additional 1,392 shares during the last quarter.

Kestra Medical Technologies Stock Performance

NASDAQ:KMTS opened at $25.54 on Monday. Kestra Medical Technologies has a 12 month low of $16.68 and a 12 month high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -10.55 and a beta of 0.62. The firm has a fifty day simple moving average of $25.53 and a two-hundred day simple moving average of $22.75.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Analysts expect that Kestra Medical Technologies will post -2.29 EPS for the current fiscal year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source